ASH 2009 meeting report - Top 10 clinically oriented abstracts in chronic myeloid leukemia

Amber Fullmer, Jorge Cortes, Hagop Kantarjian, Elias Jabbour

Research output: Contribution to journalArticle


Chronic myeloid leukemia (CML) is characterized by an acquired chromosomal translocation known as the Philadelphia chromosome. Simple target inhibition specific for Bcr-Abl can control the disease. Outcomes in CML have drastically changed following the introduction of imatinib, with the majority of patients living a normal lifespan. The abstracts presented at the 2009 American Society of Hematology (ASH) annual meeting suggested optimization of current management with new molecules more potent than imatinib and combination therapy with intention to cure CML. The most clinically relevant abstracts in CML, all of which are published in the November 2009; 114 issue of Blood, are summarized below and identified by abstract number.

Original languageEnglish (US)
Pages (from-to)283-286
Number of pages4
JournalAmerican Journal of Hematology
Issue number4
StatePublished - Apr 1 2010
Externally publishedYes


ASJC Scopus subject areas

  • Hematology

Cite this